Table 1.

PIPOH criteria for developing the health questions

Population	PsA patients of at least 16 years of age living in the Americas or Africa, particularly those with specific comorbidities of interest(TB, HIV, HB/CV, Chagas’ disease, leishmaniasis and leprosy)
Intervention	-Screening for: TB, HIV, HB/CV, Chagas’ disease, leishmaniasis, and leprosy prior to pharmacotherapy -Adverse events during pharmacotherapy -Treatment: duration and type: sequential/combination, according to domains -Response evaluation -Supportive care-Follow up
Professionals/patient	Rheumatologists, dermatologists, internists, primary care physicians, other stakeholders, patients
Outcome	-Patient Outcomes: Drug Efficacy, adverse events -Access to specialists and multidisciplinary care
Health care setting	Hospitals, clinics, doctor’s offices, primary care.

HIV human immunodeficiency virus, HB/CV hepatitis B or C virus, PsA psoriatic arthritis, TB tuberculosis